Ground Fluor receives $728K grant

By staff writers

April 15, 2014 -- Radiopharmaceutical developer Ground Fluor Pharmaceuticals has received a $728,000 phase II Small Business Innovation Research (SBIR) grant.

The grant will be used to expand research and product development of the company's proprietary chemistry for the production of F-18 fluorodopa, a PET imaging agent intended for diagnosing and managing brain tumors (such as astrocytomas and gliomas) and Parkinson's disease.

This latest grant adds to the more than $275,000 of National Science Foundation SBIR funds and state of Nebraska matching funds awarded for this research since 2011, according to the firm. The award will permit the good manufacturing practice (GMP) manufacture and distribution of a diaryliodonium intermediate for the production of F-18 fluorodopa for research and clinical use throughout the world, Ground Fluor said.

Copyright © 2014

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking